INS and cancer: We now extend these findings by demonstrating that ascending baseline insulin levels were associated with a gradual increase in cancer incidence in the control group, and that surgery was associated with 32% lower hazard (HRadj = 0.68) of overall cancer and a 34% lower hazard (HRadj = 0.66) of obesity-related cancer among women with high baseline insulin.